1. Home
  2. /
  3. Featured


December 2018

COA Comments on IPI for Medicare Part B Drugs

The Honorable Seema Verma, Administrator Centers for Medicare & Medicaid Services Department of Health and Human Services Attention: CMS-5528-ANPRM P.O. Box 8016 Baltimore, MD 21244-8013 Re: Medicare Program; International Pricing Index Model for Medicare Part B Drugs; CMS-5528- ANPRM Dear Administrator Verma: On behalf of the Board of Directors of the Community Oncology Alliance

Download (PDF) Read Full
April 2019

COA Biosimilars Position Statement

Summary: The Community Oncology Alliance (COA) is committed to advancing knowledge and acceptance of biosimilars as an important, promising element in reducing drug costs and overall health care spending, and the financial toxicity of cancer care for patients. COA will work to support biosimilars and innovative biosimilar (biologic) development with all stakeholders, including policymakers,

Download (PDF) Read Full
April 2019

CPAN at 10: A decade of Education, Advocacy, and IMPACT

Ten years ago, the Community Oncology Alliance (COA) created the Patient Advocacy Network (CPAN) to provide a powerful advocacy voice and forum for patients, survivors, caregivers, and others served by independent community oncology. The idea behind CPAN was simple: every individual who interacts with community oncology has a unique story to tell, formed by

Download (PDF) Read Full
June 2019

Community Oncology Alliance Announces ‘OCM 2.0’ Proposal, an Ambitious Reform Model to Improve Cancer Care and Reduce Costs

PTAC Application Demonstrates Community Oncology’s Continued Leadership in Providing Solutions to Cancer Care Cost and Quality Challenges The Community Oncology Alliance (COA) has submitted an innovative and ambitious reform model to improve quality, reduce costs, and provide important additional cancer care services to patients, caregivers, and survivors. Known as the “OCM 2.0”, the detailed

Download (PDF) Read Full